Body Pharm Tesamorelin 10

Researchers in South Africa can purchase tesamorelin 10 mg through JCSG.org SA, which stocks the Body Pharm-branded 10 mg lyophilised vial with batch-specific HPLC and mass-spec certificates available on request. Pricing is quoted in ZAR inclusive of VAT and confirmed at order time, with overnight cold-pack courier dispatch to registered laboratory addresses nationwide.

The procurement case rests on current evidence: a January 2026 meta-analysis in Obesity Research & Clinical Practice pooling tesamorelin trials in HIV-associated lipodystrophy reported a mean visceral adipose tissue area reduction of −27.71 cm² (95% CI −38.37 to −17.06; P < 0.001), alongside a −4.28% drop in hepatic fat and a +1.42 kg gain in lean body mass. That metabolic profile follows directly from tesamorelin's mechanism as a GHRH receptor agonist that preserves endogenous pulsatile growth hormone secretion. Tesamorelin remains the only GHRH analogue with Phase III approval for a metabolic indication.

Key Takeaways

• Body Pharm tesamorelin 10 mg is a research-grade GHRH analogue supplied as a lyophilised powder with batch-specific purity certificates
• The 2026 meta-analysis documents mean visceral adipose tissue reduction of −27.71 cm² with concurrent hepatic fat and lean mass improvements
• Tesamorelin preserves pulsatile growth hormone secretion, distinguishing it mechanistically from exogenous somatropin
• The N-terminal trans-3-hexenoyl modification extends plasma half-life to ~26 minutes, enabling once-daily dosing
• Procurement in South Africa requires institutional pharmacy clearance under the Medicines and Related Substances Act 101 of 1965

What Is Body Pharm Tesamorelin 10 mg?

Body Pharm Tesamorelin 10 mg is a research-grade lyophilised powder containing 10 mg of synthetic tesamorelin per vial. It is a 44-amino-acid GHRH analogue carrying a trans-3-hexenoic acid modification at the N-terminal tyrosine, supplied for in vitro and non-clinical laboratory use, not as recombinant human growth hormone.

The peptide has molecular formula C221H366N72O67S, a molecular weight of approximately 5135.76 Da, and CAS number 218949-48-5. The N-terminal trans-3-hexenoyl group distinguishes tesamorelin from native GHRH(1-44) by blocking dipeptidyl peptidase-IV cleavage and extending plasma half-life to approximately 26 minutes. That duration is sufficient for once-daily dosing in published clinical work, whereas unmodified GHRH(1-44) requires multiple daily injections.

Format and storage

Each Body Pharm vial is sealed under vacuum as a white lyophilised cake. Store at −20 °C until reconstitution. Batch-specific HPLC and mass-spec documentation is available on request. For comparative context within the GHRH analogue cluster, see the tesamorelin category overview and the longer-acting CJC-1295 with DAC listing.

Tesamorelin Mechanism: How GHRH Analogues Work

Tesamorelin binds the somatotroph GHRHR at the anterior pituitary and triggers cAMP-mediated release of endogenous growth hormone in physiological pulses rather than a sustained supraphysiological flood. Pulsatility is preserved because the pituitary remains the rate-limiting compartment, with negative feedback from somatostatin and IGF-1 still intact. That is the core distinction from exogenous somatropin, which bypasses the pituitary entirely and flattens the diurnal GH curve.

Downstream, pulsatile GH stimulates hepatic IGF-1 production. This GH/IGF-1 axis activation drives the lipolytic effect on visceral adipose tissue documented in the 2026 meta-analysis (mean VAT reduction −27.71 cm², 95% CI −38.37 to −17.06; P < 0.001). Researchers designing comparative protocols should encode this pharmacological distinction in their dose-timing arms, because the two mechanisms produce different metabolic outcomes.

Why the trans-3-hexenoyl modification matters

Native GHRH(1-44) has a plasma half-life under 7 minutes because dipeptidyl peptidase IV cleaves the Tyr1-Ala2 bond almost immediately. The N-terminal trans-3-hexenoic acid group on tesamorelin sterically blocks DPP-IV access, extending half-life to roughly 26 minutes and making once-daily subcutaneous dosing pharmacokinetically coherent. This is why tesamorelin entered clinical practice while unmodified GHRH(1-44) remained a research tool. For analogue comparisons within the same cluster, see the tesamorelin category overview and the DAC-stabilised CJC-1295 with DAC listing, which uses albumin binding rather than DPP-IV resistance to extend half-life.

Key Research Findings on Tesamorelin (2010–2024)

The two programmes that established tesamorelin's research pedigree are Falutz et al. (NEJM 2010) and Stanley et al. (JCEM 2012). Falutz reported approximately 18% VAT reduction over 26 weeks of 2 mg/day subcutaneous dosing in HIV-associated lipodystrophy. Stanley characterised secondary metabolic endpoints including triglyceride and adiponectin shifts alongside cognitive observations. FDA approval of Egrifta (tesamorelin 2 mg, Theratechnologies) in November 2010 for HIV-associated visceral adiposity remains the only Phase III metabolic indication for any GHRH analogue, and that regulatory anchor continues to underwrite the compound's status as a reference research tool.

The 2026 Obesity Research & Clinical Practice meta-analysis updates those original effect-size estimates. It pools randomised and non-randomised trials to a mean VAT reduction of −27.71 cm² (95% CI −38.37 to −17.06; P < 0.001), with parallel reductions in hepatic fat (−4.28%) and trunk fat (−1.18 kg) and a lean mass gain of +1.42 kg, without serious safety signals. Where newer pooled estimates exist, pre-2023 numerical endpoints for hepatic fat and lean mass deltas should be treated as potentially stale.

Research interest through 2024–2026 has broadened beyond HIV lipodystrophy into non-HIV metabolic contexts, including NAFLD-adjacent hepatic steatosis models. The 2026 narrative literature reiterates tesamorelin's specificity for visceral over subcutaneous depots. For cluster-level comparisons against an albumin-bound long-acting analogue, see the CJC-1295 with DAC listing within the broader tesamorelin category overview.

Tesamorelin vs CJC-1295 vs CJC-1295 with DAC, 2026 Comparison

Tesamorelin, CJC-1295 (no DAC) and CJC-1295 with DAC differ most sharply on plasma half-life and whether endogenous GH pulsatility is preserved. These differences determine which research question each peptide can answer.

Peptide	Half-life	Molecular Weight	Primary Research Application	Pulsatility Preserved?	Available from JCSG.org SA
Tesamorelin	~26 min	5135 Da	VAT reduction, hepatic and lipid metabolism	Yes	Yes (Body Pharm 10 mg)
CJC-1295 (no DAC)	~30 min	3367 Da	GH pulse amplification studies	Yes	Yes
CJC-1295 with DAC	~8 days	3647 Da	Sustained GH/IGF-1 elevation models	No (blunts pulsatility)	Yes

Short half-life GHRH analogues (tesamorelin, CJC-1295 no DAC) leave hypothalamic feedback loops intact and suit protocols where physiological pulse architecture is part of the endpoint. The DAC-modified analogue's albumin binding extends exposure to roughly 8 days and flattens pulse amplitude. That suits chronic-exposure models but confounds pulsatility readouts, because the two mechanisms produce fundamentally different GH secretion profiles. For cluster context, see the tesamorelin category overview and the CJC-1295 with DAC listing.

Visceral Fat Research: Why Tesamorelin Is the Reference Peptide

Tesamorelin is the reference GHRH analogue for visceral adipose tissue (VAT) research because it is the only such peptide with Phase III approval for a metabolic indication and the only one with a reproducible, quantified VAT endpoint across more than a decade of trials. Selective GHRH-receptor agonism amplifies endogenous GH pulses without bypassing hypothalamic feedback, which is why VAT reduction translates cleanly into measurable hepatic-fat and lipid-profile changes in published models.

The 2026 Obesity Research & Clinical Practice meta-analysis refined the original Falutz signal to a pooled VAT area reduction of −27.71 cm² (95% CI −38.37 to −17.06; P < 0.001), with hepatic fat down 4.28% and lean mass up 1.42 kg, and no major glucose disruption recorded. Validated CT-based L4-L5 VAT quantification protocols make the endpoint portable across labs, which is why the effect size reproduces across different research centres.

AOD-9604 should not be substituted in these models. It is a synthetic GH fragment (residues 176-191) acting on lipolytic pathways, not a GHRH-R agonist, and produces no GH pulse. That mechanistic difference means AOD-9604 cannot replicate tesamorelin's metabolic profile in comparative studies. For the parent cluster, see the tesamorelin category overview.

Body Pharm Tesamorelin 10 mg, Product Specifications

Body Pharm tesamorelin 10 mg is supplied as a sterile lyophilised powder in a sealed glass vial, sold strictly as a research chemical for in vitro and laboratory use only (not for human consumption). Each vial contains 10 mg of tesamorelin acetate, manufactured to a ≥98% HPLC purity specification consistent with research-grade GHRH analogue standards. Batch-specific HPLC and mass-spectrometry certificates of analysis are available on request from the supplier's QA contact. Verify purity before use in any quantitative research protocol.

Store unreconstituted vials at −20 °C, protected from light. Reconstitution with bacteriostatic water (0.9% benzyl alcohol) is the standard recommendation for short-term laboratory handling. Reconstituted aliquots should be held at 2-8 °C and used within established peptide-stability windows for GHRH analogues.

For procurement comparison against adjacent GHRH-axis peptides in the same cluster, see the tesamorelin category overview and the long-acting analogue Body Pharm CJC-1295 with DAC.

Research Notes

Specifications reviewed and confirmed against supplier documentation. Review date: March 2026. Researchers should verify the current batch CoA at the point of order, as purity specifications and reconstitution guidance are batch-dependent and may shift between manufacturing runs.

Buying Tesamorelin 10 mg in South Africa, 2026 Guide

Researchers can purchase tesamorelin 10 mg in South Africa directly through JCSG.org, with ZAR checkout. As of March 2026, the Body Pharm 10 mg vial is flagged "stock arriving soon". Live ZAR pricing (VAT inclusive) will be inserted on the product page at restock and time-stamped on this entry.

Orders ship via tracked courier in discreet outer packaging, with an insulated cold-chain protocol (ice packs, insulated mailer) appropriate for lyophilised GHRH analogues during 24-48 hour domestic transit. Tracking numbers are issued at dispatch. Delivery is restricted to South African addresses because cold-chain integrity is critical for peptide stability.

Research chemicals in South Africa fall under the Medicines and Related Substances Act 101 of 1965, with the South African Health Products Regulatory Authority (SAHPRA) as the responsible regulator. Body Pharm tesamorelin 10 mg is supplied as a research chemical for in vitro and laboratory use only; it is not a SAHPRA-registered medicine and is not intended for human or veterinary administration. Institutional purchasers should clear procurement with their pharmacy licence holder before any clinical handling.

For adjacent GHRH-axis stock, see the tesamorelin category overview or the long-acting CJC-1295 with DAC listing.

Frequently Asked Questions, Tesamorelin Research SA